GlycArt Biotechnology AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlycArt Biotechnology AG
Japan has granted reimbursement prices to two anticancer antibodies and other products as it supports the availability of new, higher priced therapies in areas of high medical need, including through early access, while Takeda’s Entyvio is also set for launch.
Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.
Basel-based BioMedPartners has launched a new CHF75m venture capital fund, BioMedInvest III, boosting financing opportunities for startups and mid-sized biotechs in the sparse European market.
GamaMabs Pharma SA is one of the latest contenders aiming to boost the biological activity of antibodies by altering their attached sugar groups. The company, located in Toulouse, France, was founded in June 2013 to develop therapeutic antibody treatments for gynecologic cancers, using core technologies licensed from the French Laboratories for Biotechnologies.